SK16272000A3 - Použitie a kombinácie kabergolínu a pramipexolu - Google Patents

Použitie a kombinácie kabergolínu a pramipexolu Download PDF

Info

Publication number: SK16272000A3
Authority: SK; Slovakia
Prior art keywords: cabergoline; pramipexole; patient; day; treatment
Prior art date: 1998-05-15

Application number

SK1627-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Baltazar Gomez-Mancilla

Original Assignee

Pharmacia And Upjohn Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

1999-05-07

Publication date

2001-05-10

1999-05-07 Application filed by Pharmacia And Upjohn Company filed Critical Pharmacia And Upjohn Company

2001-05-10 Publication of SK16272000A3 publication Critical patent/SK16272000A3/sk

Links

FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims abstract description 53
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title claims abstract description 50
229960004596 cabergoline Drugs 0.000 title claims abstract description 50
229960003089 pramipexole Drugs 0.000 title claims abstract description 48
208000018737 Parkinson disease Diseases 0.000 title claims abstract description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
201000010099 disease Diseases 0.000 title description 8
238000011282 treatment Methods 0.000 claims abstract description 32
208000015114 central nervous system disease Diseases 0.000 claims abstract description 4
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 35
239000003814 drug Substances 0.000 claims description 24
238000011287 therapeutic dose Methods 0.000 claims description 16
208000001089 Multiple system atrophy Diseases 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 12
230000003442 weekly effect Effects 0.000 claims description 9
230000000750 progressive effect Effects 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 4
238000011284 combination treatment Methods 0.000 abstract description 2
229940079593 drug Drugs 0.000 description 18
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 17
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 17
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 15
230000000694 effects Effects 0.000 description 9
229960004502 levodopa Drugs 0.000 description 8
229960003638 dopamine Drugs 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
230000006872 improvement Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
239000003826 tablet Substances 0.000 description 6
239000000556 agonist Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
229940101972 mirapex Drugs 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
206010034010 Parkinsonism Diseases 0.000 description 3
229960002802 bromocriptine Drugs 0.000 description 3
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
210000002637 putamen Anatomy 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
206010006100 Bradykinesia Diseases 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
208000006083 Hypokinesia Diseases 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
230000001144 postural effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000004448 titration Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
APVQOOKHDZVJEX-UHFFFAOYSA-N 6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1C(NCCC)CCC2=C1SC(N)=N2 APVQOOKHDZVJEX-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000036632 Brain mass Diseases 0.000 description 1
VKWQXBRYHOZFES-GRLJVJLHSA-N CCCN[C@H](CC1=C2)NCC1=C[S+]2N.O.Cl.Cl Chemical compound CCCN[C@H](CC1=C2)NCC1=C[S+]2N.O.Cl.Cl VKWQXBRYHOZFES-GRLJVJLHSA-N 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
-1 Sinemet or Prelopa Chemical compound 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000064 cholinergic agonist Substances 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000004424 eye movement Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
229950001476 idazoxan Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
229960003587 lisuride Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000007121 neuropathological change Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
229940001089 sinemet Drugs 0.000 description 1
238000002603 single-photon emission computed tomography Methods 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

SK1627-2000A 1998-05-15 1999-05-07 Použitie a kombinácie kabergolínu a pramipexolu SK16272000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8561998P	1998-05-15	1998-05-15
US8794398P	1998-06-04	1998-06-04
PCT/US1999/007024 WO1999059563A2 (fr)	1998-05-15	1999-05-07	Cabergoline et pramipexole: nouvelles utilisations et combinaisons

Publications (1)

Publication Number	Publication Date
SK16272000A3 true SK16272000A3 (sk)	2001-05-10

Family

ID=26772918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1627-2000A SK16272000A3 (sk)	1998-05-15	1999-05-07	Použitie a kombinácie kabergolínu a pramipexolu

Country Status (22)

Country	Link
US (1)	US6503920B1 (fr)
EP (1)	EP1076559B1 (fr)
JP (1)	JP2002515425A (fr)
KR (3)	KR20060056417A (fr)
CN (1)	CN1301159A (fr)
AT (1)	ATE310517T1 (fr)
AU (1)	AU748629B2 (fr)
BR (1)	BR9909917A (fr)
CA (1)	CA2327299A1 (fr)
DE (1)	DE69928521T2 (fr)
DK (1)	DK1076559T3 (fr)
EA (4)	EA200300125A1 (fr)
ES (1)	ES2251191T3 (fr)
HU (1)	HUP0101803A3 (fr)
IL (1)	IL139682A0 (fr)
NO (1)	NO20005757L (fr)
NZ (2)	NZ526071A (fr)
PL (1)	PL344574A1 (fr)
SG (1)	SG121745A1 (fr)
SK (1)	SK16272000A3 (fr)
TR (1)	TR200003356T2 (fr)
WO (1)	WO1999059563A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0007309D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10138275A1 (de) *	2001-08-10	2003-02-27	Boehringer Ingelheim Pharma	Verbindungen zur Beseitigung der Anhedonie
DE10148233A1 (de) *	2001-09-28	2003-04-10	Boehringer Ingelheim Pharma	Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
PA8578501A1 (es)	2002-07-25	2005-02-04	Pharmacia Corp	Forma de dosificacion una vez al dia de pramipexol
GB0221513D0 (en) *	2002-09-17	2002-10-23	Generics Uk Ltd	Novel compounds and processes
CN101022788B (zh)	2004-08-13	2010-11-10	贝林格尔·英格海姆国际有限公司	包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru)	2004-08-13	2011-02-25	Берингер Ингельхайм Интернациональ Гмбх	композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
EP1988875A2 (fr) *	2006-02-10	2008-11-12	Boehringer Ingelheim International GmbH	Formulation a liberation modifiee
PL232974B1 (pl) *	2015-12-09	2019-08-30	Ofta Spolka Z Ograniczona Odpowiedzialnoscia	Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4526892A (en) *	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DE3937271A1 (de) *	1989-11-09	1991-05-16	Boehringer Ingelheim Kg	Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
WO1995005176A1 (fr) *	1993-08-18	1995-02-23	Alcon Laboratories, Inc.	Derives de l'ergoline pour le traitement du glaucome
US5496836A (en) *	1994-05-05	1996-03-05	Mount Sinai School Of Medicine Of The City University Of New York	Use of famotidine and related compounds in the treatment of movement disorders
US5650420A (en) *	1994-12-15	1997-07-22	Pharmacia & Upjohn Company	Pramipexole as a neuroprotective agent
FR2728374A1 (fr) *	1994-12-15	1996-06-21	Aerospatiale	Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol

1999
- 1999-05-07 KR KR1020067007720A patent/KR20060056417A/ko not_active Ceased
- 1999-05-07 KR KR1020067007719A patent/KR20060056416A/ko not_active Ceased
- 1999-05-07 EA EA200300125A patent/EA200300125A1/ru unknown
- 1999-05-07 AT AT99919772T patent/ATE310517T1/de not_active IP Right Cessation
- 1999-05-07 SK SK1627-2000A patent/SK16272000A3/sk unknown
- 1999-05-07 CA CA002327299A patent/CA2327299A1/fr not_active Abandoned
- 1999-05-07 JP JP2000549228A patent/JP2002515425A/ja active Pending
- 1999-05-07 DK DK99919772T patent/DK1076559T3/da active
- 1999-05-07 NZ NZ526071A patent/NZ526071A/en unknown
- 1999-05-07 TR TR2000/03356T patent/TR200003356T2/xx unknown
- 1999-05-07 CN CN99805219A patent/CN1301159A/zh active Pending
- 1999-05-07 AU AU37419/99A patent/AU748629B2/en not_active Ceased
- 1999-05-07 PL PL99344574A patent/PL344574A1/xx not_active IP Right Cessation
- 1999-05-07 WO PCT/US1999/007024 patent/WO1999059563A2/fr not_active Ceased
- 1999-05-07 DE DE69928521T patent/DE69928521T2/de not_active Expired - Fee Related
- 1999-05-07 ES ES99919772T patent/ES2251191T3/es not_active Expired - Lifetime
- 1999-05-07 SG SG200206791A patent/SG121745A1/en unknown
- 1999-05-07 HU HU0101803A patent/HUP0101803A3/hu unknown
- 1999-05-07 EA EA200001192A patent/EA004474B1/ru not_active IP Right Cessation
- 1999-05-07 IL IL13968299A patent/IL139682A0/xx unknown
- 1999-05-07 BR BR9909917-9A patent/BR9909917A/pt not_active Application Discontinuation
- 1999-05-07 US US09/674,838 patent/US6503920B1/en not_active Expired - Fee Related
- 1999-05-07 NZ NZ508184A patent/NZ508184A/en unknown
- 1999-05-07 EP EP99919772A patent/EP1076559B1/fr not_active Expired - Lifetime
- 1999-05-07 KR KR1020007012760A patent/KR20010043612A/ko not_active Ceased
- 1999-05-07 EA EA200200955A patent/EA200200955A1/ru unknown
- 1999-05-07 EA EA200300124A patent/EA200300124A1/ru unknown
2000
- 2000-11-14 NO NO20005757A patent/NO20005757L/no unknown

Also Published As

Publication number	Publication date
KR20060056417A (ko)	2006-05-24
NO20005757D0 (no)	2000-11-14
PL344574A1 (en)	2001-11-05
AU3741999A (en)	1999-12-06
DE69928521D1 (de)	2005-12-29
NO20005757L (no)	2000-11-14
NZ526071A (en)	2004-11-26
HUP0101803A2 (hu)	2002-03-28
EA004474B1 (ru)	2004-04-29
KR20010043612A (ko)	2001-05-25
ES2251191T3 (es)	2006-04-16
EA200200955A1 (ru)	2002-12-26
IL139682A0 (en)	2002-02-10
BR9909917A (pt)	2000-12-26
HUP0101803A3 (en)	2002-10-28
EA200001192A1 (ru)	2001-04-23
WO1999059563A3 (fr)	2000-04-13
DK1076559T3 (da)	2006-01-16
JP2002515425A (ja)	2002-05-28
CA2327299A1 (fr)	1999-11-25
US6503920B1 (en)	2003-01-07
ATE310517T1 (de)	2005-12-15
EA200300124A1 (ru)	2003-10-30
EP1076559B1 (fr)	2005-11-23
KR20060056416A (ko)	2006-05-24
EA200300125A1 (ru)	2003-06-26
EP1076559A2 (fr)	2001-02-21
NZ508184A (en)	2004-01-30
CN1301159A (zh)	2001-06-27
TR200003356T2 (tr)	2001-03-21
DE69928521T2 (de)	2006-07-27
WO1999059563A2 (fr)	1999-11-25
SG121745A1 (en)	2006-05-26
AU748629B2 (en)	2002-06-06

Publication	Publication Date	Title
JP4796219B2 (ja)	2011-10-19	神経保護剤としてのプラミペキソールの使用
US9585878B2 (en)	2017-03-07	Treatment of BDNF-related disorders using laquinimod
CN104487062B (zh)	2017-08-04	用于治疗帕金森病的治疗方法
EP3185859B1 (fr)	2019-07-17	Nouvelles approches thérapeutiques pour le traitement de la maladie de parkinson
CN108420819A (zh)	2018-08-21	用于治疗神经障碍的新组合物
WO1998007431A1 (fr)	1998-02-26	Inhibiteurs de la cholinesterase pour le traitement de la maladie de parkinson
SK16272000A3 (sk)	2001-05-10	Použitie a kombinácie kabergolínu a pramipexolu
CN111093647A (zh)	2020-05-01	用于治疗共核蛋白病的他汀类组合物和方法
US20030045539A1 (en)	2003-03-06	Cabergoline and pramipexole: new uses and combinations
AU760439B2 (en)	2003-05-15	Cabergoline and pramipexole: new uses and combinations
CZ20004199A3 (cs)	2001-05-16	Použití kabergolinu a/nebo pramipexolu
WO2001022960A1 (fr)	2001-04-05	Traitement de l'asphyxie par le monoxyde de carbone
MXPA00011219A (es)	2001-07-31	Cabergolina y pramipexol para el tratamiento de enfermedades del sistema nervioso central, en especial la enfermedad de parkinson
EP1591119A2 (fr)	2005-11-02	Pramipexole pour le traitement des maladies du système nerveux central, en particulier la maladie de Parkinson
Rodríguez	1972	Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa.
HK1036416A (en)	2002-01-04	Cabergoline and pramipexole: for treating cns, diseases, especially parkinson's disease
US20250011277A1 (en)	2025-01-09	Modified forms of ambroxol for therapeutic use
KR20250023997A (ko)	2025-02-18	코카인 중독을 치료하는 방법에서의 5-메톡시-2-아미노인단 (“meai”)의 용도
WO2004105756A2 (fr)	2004-12-09	Combinaison contenant un agent neuroprotecteur et un agent se fixant a la gadph, et utilisation pharmaceutique associee